NasdaqCM:RGCPharmaceuticals
DOJ Probe Puts Regencell Bioscience Finances And Investor Outlook Under Strain
The U.S. Department of Justice has opened an investigation into Regencell Bioscience Holdings for potential violations of federal securities laws.
Authorities have requested extensive documentation related to the company’s operations, finances, and accounting.
Regencell expects substantial legal expenses and acknowledges the possibility of fines or settlements that may not be fully covered by insurance.
For shareholders of Regencell Bioscience Holdings, ticker NasdaqCM:RGC, this...